Gal Markel
0000-0003-4835-891X
Publication & Citation Trends
Publications
335 total
PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis
Cited by 0
Semantic Scholar
CT Body Composition Changes Predict Survival in Immunotherapy-Treated Cancer Patients: A Retrospective Cohort Study
Cited by 0
Semantic Scholar
Challenges in interpreting survival metrics in clinical trials: the utility of restricted mean survival analyses. OA
Cited by 7
Semantic Scholar
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring OA
Cited by 2
Semantic Scholar
Abstract A064: Dynamics in automatic CT based body composition and blood biomarkers in predicting mortality on immune therapy treated solid malignancy patients
Cited by 0
Semantic Scholar
Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation
Cited by 1
Semantic Scholar
Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time OA
Cited by 6
Semantic Scholar
731: Assessing metastasis-directed therapy in oligometastatic disease using restricted mean survival time
Cited by 0
Semantic Scholar
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC data OA
Cited by 0
Semantic Scholar
Gender Gap in Leadership of Clinical Trials.
Cited by 14
Semantic Scholar
Research Topics
Cytokine Signaling Pathways and Interactions
(108)
Cancer Immunotherapy and Biomarkers
(63)
Immunotherapy and Immune Responses
(54)
CAR-T cell therapy research
(53)
Myeloproliferative Neoplasms: Diagnosis and Treatment
(45)
Affiliations
Ben-Gurion University of the Negev
Brigham and Women's Hospital
Harvard University
University of Cape Town
George Mason University